GSK agreed to acquire Nuvalent for $10.6 billion, positioning the deal to strengthen its precision oncology portfolio in ROS1- and ALK-driven NSCLC. Nuvalent’s pipeline includes zidesamtinib (ROS1) and eladalkib (ALK), with FDA decision target dates later this year and both programs having Breakthrough Therapy and Orphan Drug designations. GSK framed the acquisition as a multi-product move to address potential efficacy and/or tolerability gaps, particularly for brain-penetrant targeted treatments. The transaction also underscores the continued valuation premium being placed on late-stage, biomarker-defined oncology assets with differentiated resistance biology.